Transforming the Future of Neuropsychiatry
Draig Therapeutics is developing transformative, best-in-class neuropsychiatric therapies to restore the brain to a healthier state, enabling patients to live their best lives.
The Draig Difference
A More Precise Approach to Brain Health
Anchored by decades of scientific learnings and drug development experience, Draig's highly specific neuromodulators are designed to enable safe, precise modulation of the major neurocircuits underlying neuropsychiatric disorders.
Our Pipeline
Pioneering New Treatments for Depression and Beyond
Our lead program, DT-101, is a Phase 2 AMPA receptor potentiator designed to address the profound unmet need in major depressive disorder.
Draig is also advancing highly selective GABAA receptor modulators with strong therapeutic potential for a range of prevalent and underserved neuropsychiatric disorders towards clinical development.
Commitment to Patients
Patients Help Shape Everything We Do
Patients are central to our goal of developing transformative, best-in-class neuropsychiatric therapies. We know that developing such therapies requires more than rigorous science and strong execution. That's why we are committed to co-creating in partnership with patients and their care partners.
The Future of Brain Health Starts Here
Whether you're a patient, caregiver, researcher, investor, or member of the press, we'd love to hear from you.
